Comparative pharmacokinetics of polymyxin B in critically ill elderly patients with extensively drug-resistant gram-negative bacteria infections

被引:0
|
作者
Zeng, Juan [1 ]
Leng, Bing [2 ]
Guan, Xiaoyan [1 ]
Jiang, Shuangyan [1 ]
Xie, Maoyu [3 ]
Zhu, Wenying [1 ]
Tang, Yue [1 ]
Zhang, Lin [1 ]
Sha, Jing [1 ]
Wang, Tengfei [1 ]
Ding, Min [1 ]
Guo, Nan [2 ]
Jiang, Jinjiao [1 ]
机构
[1] Shandong First Med Univ, Dept Crit Care Med, Shandong Prov Hosp Affiliated, Jinan, Shandong, Peoples R China
[2] Shandong First Med Univ, Dept Pharm, Shandong Prov Hosp Affiliated, Jinan, Shandong, Peoples R China
[3] Shandong First Med Univ, Dept Emergency, Shandong Prov Hosp Affiliated, Jinan, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
polymyxin B; pharmacokinetics; elderly; critical care; total body weight; renal function;
D O I
10.3389/fphar.2024.1347130
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Elderly patients are more prone to develop acute kidney injury during infections and polymyxin B (PMB)-associated nephrotoxicity than young patients. The differential response to PMB between the elderly and young critically ill patients is unknown. We aimed to assess PMB exposure in elderly patients compared with young critically ill patients, and to determine the covariates of PMB pharmacokinetics in critically ill patients. Methods: Seventeen elderly patients (age >= 65 years) and six young critically ill patients (age < 65 years) were enrolled. Six to eight blood samples were collected during the 12 h intervals after at least six doses of intravenous PMB in each patient. PMB plasma concentrations were quantified by high-performance liquid chromatography-tandem mass spectrometry. The primary outcome was PMB exposure as assessed by the area under the concentration-time curve over 24 h at steady state (AUC(ss, 0-24 h)). Results and Discussion: The elderly group had lower total body weight (TBW) and higher Charlson comorbidity scores than young group. Neither AUC(ss, 0-24 h) nor normalized AUC(ss, 0-24 h) (adjusting AUC for the daily dose in mg/kg of TBW) was significantly different between the elderly group and young group. The half-life time was longer in the elderly patients than in young patients (11.21 vs 6.56 h respectively, p = 0.003). Age and TBW were the covariates of half-life time (r = 0.415, p = 0.049 and r = -0.489, p = 0.018, respectively). TBW was the covariate of clearance (r = 0.527, p = 0.010) and AUC(ss, 0-24 h) (r = -0.414, p = 0.049). Patients with AUC(ss, 0-24 h) >= 100 mg<middle dot>h/L had higher baseline serum creatinine levels and lower TBW than patients with AUC(ss, 0-24 h) < 50 mg<middle dot>h/L or patients with AUC(ss, 0-24 h) 50-100 mg<middle dot>h/L. The PMB exposures were comparable in elderly and young critically ill patients. High baseline serum creatinine levels and low TBW was associated with PMB overdose.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Effectiveness and safety of polymyxin B for the treatment of infections caused by extensively drug-resistant Gram-negative bacteria in Thailand
    Ngamprasertchai, Thundon
    Boonyasiri, Adhiratha
    Charoenpong, Lantharita
    Nimitvilai, Sireethorn
    Lorchirachoonkul, Narisorn
    Wattanamongkonsil, Luksame
    Thamlikitkul, Visanu
    [J]. INFECTION AND DRUG RESISTANCE, 2018, 11 : 1219 - 1224
  • [2] Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations
    Xie, Jiao
    Roberts, Jason A.
    Lipman, Jeffrey
    Cai, Yan
    Wang, Haitao
    Zhao, Nuannuan
    Xu, Xiaona
    Yang, Shan
    Li, Youjia
    Zhang, Kanghuai
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (06)
  • [3] Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections
    Wang, Peile
    Zhang, Qiwen
    Feng, Min
    Sun, Tongwen
    Yang, Jing
    Zhang, Xiaojian
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [4] Use of Tigecycline in Pediatric Patients With Infections Predominantly Due to Extensively Drug-Resistant Gram-Negative Bacteria
    Iosifidis, Elias
    Violaki, Asimenia
    Michalopoulou, Evangelia
    Volakli, Elena
    Diamanti, Elisavet
    Koliouskas, Dimitrios
    Antachopoulos, Charalampos
    Drossou-Agakidou, Vasiliki
    Sdougka, Maria
    Roilides, Emmanuel
    [J]. JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2017, 6 (02) : 123 - 128
  • [5] Intravenous fosfomycin in patients with liver disease for extensively drug-resistant Gram-negative bacteria
    Pyrpasopoulou, Athina
    Pitsava, Georgia
    Iosifidis, Elias
    Imvrios, George
    Massa, Eleni
    Mouloudi, Eleni
    Goulis, Ioannis
    Chatzidrosou, Eleni
    Antachopoulos, Charalampos
    Fouzas, Ioannis
    Roilides, Emmanuel
    [J]. JOURNAL OF INFECTION, 2018, 77 (05) : 452 - 454
  • [6] Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria
    Pontikis, Konstantinos
    Karaiskos, Ilias
    Bastani, Styliani
    Dimopoulos, George
    Kalogirou, Michalis
    Katsiari, Maria
    Oikonomou, Angelos
    Poulakou, Garyphallia
    Roilides, Emmanuel
    Giamarellou, Helen
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2014, 43 (01) : 52 - 59
  • [7] Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections
    Wang, Peile
    Liu, Dongmei
    Sun, Tongwen
    Zhang, Xiaojian
    Yang, Jing
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (5-6)
  • [8] Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili, Abdollah
    Izanloo, Ahdieh
    Rastegar, Mostafa
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2023, 21 (04) : 387 - 429
  • [9] The use of cefiderocol for extensively drug-resistant gram-negative bacterial infections: a case series
    Sadyrbaeva-Dolgova, S.
    Martin-Roldan, A.
    Espinosa-Rodriguez, A.
    Jimenez-Morles, A.
    Hidalgo-Tenorio, C.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (06) : 1553 - 1554
  • [10] Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections
    Kwa, Andrea L. H.
    Lim, Tze-Peng
    Low, Jenny G. H.
    Hou, JingGuo
    Kurup, Asok
    Prince, Randall A.
    Tam, Vincent H.
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2008, 60 (02) : 163 - 167